BD inks definitive TriPath purchase pact
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson's purchase of TriPath Imaging under a definitive $350 mil. agreement, announced Sept. 8, is in line with the terms of BD's initial mid-August purchase offer (1"The Gray Sheet" Aug. 21, 2006, p. 3). TriPath's SurePath cervical cancer screening technology and molecular oncology diagnostics will dovetail with BD's flow cytometry systems for the detection of lymphoma and leukemia to advance BD's position in cancer diagnostics, BD says. Combination of the complementary businesses builds on the firms' 2001 collaboration to develop molecular diagnostics for various forms of cancer. BD expects the deal to close by year-end, pending TriPath shareholder approval and antitrust clearance...